MedTrace Logo

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

NCT04258371 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-05-17

No results posted yet for this study

Summary

This study aims to elucidate the impact of SGLT2 inhibition on peripheral vascular function, renal function, fluid volume, neurohormonal activation and inflammatory/fibrotic pathways in patients with T2D at high cardiovascular risk and non-T2D patients.

Conditions

  • Cardiovascular Risk Factor

Interventions

DRUG

Dapagliflozin 10 MG

Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks

DRUG

Placebo oral tablet

Placebo once daily for 12 weeks

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    collaborator OTHER

  • MOUNT SINAI HOSPITAL

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • David ZI Cherney, MD PhD FRCPC · University Health Network, Toronto General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-10
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04258371 on ClinicalTrials.gov